About Glioblastoma (“GBM”)
October 25, 2016 | Video
October 25, 2016 | Video
Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.
Adam Finn, M.D., Ph.D., discusses Data from the Sci-B-Vac® Phase 3 program at EASL.
VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.
David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901.
In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.
Sci-B-Vac™ is a licensed third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 300,000 patients. Sci-B-Vac™ is currently approved for use in Israel and in 14 other countries.
Medulloblastoma is the most common malignant primary brain tumor in children.
Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.
VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines.
